Literature DB >> 15231250

New drugs for treatment of multiple myeloma.

Benedetto Bruno1, Marcello Rotta, Luisa Giaccone, Massimo Massaia, Alessandra Bertola, Antonio Palumbo, Mario Boccadoro.   

Abstract

Multiple myeloma (MM) is a disease of plasma cells that has fatal consequences. New insights into the biology of MM have identified molecular mechanisms that hold promise as therapeutic targets. Laboratory and preclinical studies have shown that intracellular regulatory proteins and functional interactions between MM cells and the bone-marrow microenvironment have a pivotal role in the growth, survival, drug resistance, and malignant progression of MM cells. New agents associated with molecular targets have prompted clinical investigators to design new treatment strategies initially for advanced MM and later for newly diagnosed MM, with encouraging preliminary results. Here, we discuss the mechanisms of action of these new rational drugs and the preliminary clinical outcomes of a new treatment regimen for MM.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15231250     DOI: 10.1016/S1470-2045(04)01511-6

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  10 in total

1.  Clinical impact of immunophenotypic remission after allogeneic hematopoietic cell transplantation in multiple myeloma.

Authors:  L Giaccone; L Brunello; M Festuccia; M Gilestro; E Maffini; F Ferrando; E Talamo; R Passera; M Boccadoro; P Omedè; B Bruno
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

2.  Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma.

Authors:  Luisa Giaccone; Barry Storer; Francesca Patriarca; Marcello Rotta; Roberto Sorasio; Bernardino Allione; Fabrizio Carnevale-Schianca; Moreno Festuccia; Lucia Brunello; Paola Omedè; Sara Bringhen; Massimo Aglietta; Alessandro Levis; Nicola Mordini; Andrea Gallamini; Renato Fanin; Massimo Massaia; Antonio Palumbo; Giovannino Ciccone; Rainer Storb; Ted A Gooley; Mario Boccadoro; Benedetto Bruno
Journal:  Blood       Date:  2011-04-13       Impact factor: 22.113

3.  Efficacy and safety of thalidomide in patients with hepatocellular carcinoma.

Authors:  Hsueh-Erh Chiou; Tsang-En Wang; Ying-Yue Wang; Hui-Wen Liu
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

Review 4.  Multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2010-02-11       Impact factor: 3.909

5.  Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy.

Authors:  Paul Richardson; Constantine Mitsiades; Jacob Laubach; Robert Schlossman; Irene Ghobrial; Teru Hideshima; Nikhil Munshi; Kenneth Anderson
Journal:  Core Evid       Date:  2010-06-15

6.  Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.

Authors:  Tuoen Liu; Zhiqiang Fei; Kalyan J Gangavarapu; Senyo Agbenowu; Alok Bhushan; James C K Lai; Christopher K Daniels; Shousong Cao
Journal:  Leuk Res       Date:  2013-07-18       Impact factor: 3.156

7.  Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy.

Authors:  Mario Boccadoro; Gareth Morgan; Jamie Cavenagh
Journal:  Cancer Cell Int       Date:  2005-06-01       Impact factor: 5.722

8.  Problems monitoring response in multiple myeloma.

Authors:  Conor D Collins
Journal:  Cancer Imaging       Date:  2005-11-23       Impact factor: 3.909

9.  Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer.

Authors:  Sanaz Taromi; Florentine Lewens; Ruza Arsenic; Dagmar Sedding; Jörg Sänger; Almut Kunze; Markus Möbs; Joana Benecke; Helma Freitag; Friederike Christen; Daniel Kaemmerer; Amelie Lupp; Mareike Heilmann; Hedwig Lammert; Claus-Peter Schneider; Karen Richter; Michael Hummel; Britta Siegmund; Meike Burger; Franziska Briest; Patricia Grabowski
Journal:  Oncotarget       Date:  2017-09-23

10.  Somatostatin and opioid receptors do not regulate proliferation or apoptosis of the human multiple myeloma U266 cells.

Authors:  Céline Kerros; Thibault Cavey; Brigitte Sola; Philippe Jauzac; Stéphane Allouche
Journal:  J Exp Clin Cancer Res       Date:  2009-06-07
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.